2024-03-28T21:12:49Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_385659ABD730
2024-03-23T02:12:27Z
serval:BIB_385659ABD730
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.
10.1093/annonc/mdy120
000438508100018
29648580
Wirsching
H.G.
author
Tabatabai
G.
author
Roelcke
U.
author
Hottinger
A.F.
author
Jörger
F.
author
Schmid
A.
author
Plasswilm
L.
author
Schrimpf
D.
author
Mancao
C.
author
Capper
D.
author
Conen
K.
author
Hundsberger
T.
author
Caparrotti
F.
author
von Moos
R.
author
Riklin
C.
author
Felsberg
J.
author
Roth
P.
author
Jones
DTW
author
Pfister
S.
author
Rushing
E.J.
author
Abrey
L.
author
Reifenberger
G.
author
Held
L.
author
von Deimling
A.
author
Ochsenbein
A.
author
Weller
M.
author
article
2018-06-01
Annals of oncology
1569-8041
0923-7534
journal
29
6
1423-1430
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological/therapeutic use
Bevacizumab/therapeutic use
Chemoradiotherapy/mortality
Female
Follow-Up Studies
Glioblastoma/drug therapy
Glioblastoma/pathology
Glioblastoma/radiotherapy
Humans
Male
Prognosis
Quality of Life
Radiation Dose Hypofractionation
Survival Rate
eng
60_published
true
peer-reviewed
Publication types: Clinical Trial, Phase II ; Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish